Business Wire
30 Jan 2026, 14:29 UTC · 33w ago
Incyte Announces Positive CHMP Opinion for Zynyz® (retifanlimab) for First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC)
Verdict
Headline takes no side. We score INCY +0.80 — strongly bullish.
- Expected · INCY
+0.80strongly bullish
−1 bearish0bullish +1More positive than 86% of ticker scores this week
